Black Diamond Therapeutics Inc (NAS:BDTX)
$ 3.31 0.09 (2.8%) Market Cap: 187.03 Mil Enterprise Value: 82.76 Mil PE Ratio: 0 PB Ratio: 1.68 GF Score: 41/100

Black Diamond Therapeutics Inc at Piper Sandler Healthcare Conference Transcript

Dec 01, 2022 / 02:30PM GMT
Release Date Price: $2.06 (-2.37%)
David M. Epstein
Black Diamond Therapeutics, Inc. - Co-Founder, President, & CEO

Okay, thank you. Just to remind, everybody this presentation contains forward-looking statements and data. So happy to be here to present the Black Diamond story. So Black Diamond is a unique precision medicine company. We're unique because we have developed MasterKey inhibitors that target families of oncogenic mutations.

And we do this with the intent of expanding the patient population that are treatable by a single therapy. Well, that will become evident as we go through the presentation today. We do this in a unique manner. We use population level DNA sequencing information from patients themselves.

We annotate those mutations. We've grouped them into families. And then we build small-molecule therapies that target the family of mutations, not individual mutations. And so in this way, we are able to expand the patient population that is treatable with a single therapy. We have two programs in clinical development. We'll come to that in just a moment.

But it's important to point out that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot